Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$16.98 USD
+0.17 (1.01%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $16.98 0.00 (0.00%) 6:46 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TEVA 16.98 +0.17(1.01%)
Will TEVA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TEVA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TEVA
TEVA's Ajovy Meets Goal in Migraine Prevention Study for Kids
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
TEVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
Here's Why You Should Consider Buying Alvotech (ALVO) Stock
AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
Other News for TEVA
Hims & Hers appoints former Novo Nordisk president to board
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Teva's Migraine Treatment Found Effective For Children As Young As 6
Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine
Axsome Therapeutics price target lowered by $2 at BofA, here's why